Guerin Marc B, Treacy Maxwell P, O'Keeffe Michael
1 Laser Suite, Mater Private Hospital, Dublin - Ireland.
Eur J Ophthalmol. 2014 Jan-Feb;24(1):10-3. doi: 10.5301/ejo.5000298. Epub 2013 May 24.
To evaluate the efficacy, safety, refractive predictability, and complications 12 months following the implantation of a foldable toric phakic intraocular lens (PIOL) for the correction of myopic astigmatism.
Uncorrected visual acuity (UCVA) and best-corrected distance visual acuity (CDVA), subjective and objective manifest refraction, endothelial cell count (ECC), intraocular pressure, biomicroscopy findings, and patient-reported symptoms were the main parameters recorded pre and post the implantation of an Artiflex toric PIOL.
Twenty-eight eyes of 19 patients with preoperative myopia ranging from -1.00 D to -12.00 D and with astigmatism ranging from -1.00 D to -5.50 D had the Artiflex toric PIOL inserted to correct refractive error. Postoperatively, all eyes had UCVA of at least 6/12, 94% of at least 6/9, and 58% of at least 6/6. The CDVA improved in 38% of eyes and vision deteriorated by one line in one eye. Postoperative mean refractive spherical equivalent was -0.25 D (range -1.25 D to 0.00 D) with mean astigmatism being -0.60 D (range -1.50 D to 0.00 D). The ECC decreased by a mean of 6.17% (SD 5.63%) at 12 months when compared with the preoperative baseline.
The Artiflex toric PIOL is an efficacious, predictable, and safe method of treating moderate to high refractive error with astigmatism.
评估可折叠环曲面有晶状体眼人工晶状体（PIOL）植入术后12个月时矫正近视散光的疗效、安全性、屈光预测性及并发症。
记录Artiflex环曲面PIOL植入术前和术后的主要参数，包括裸眼视力（UCVA）、最佳矫正远视力（CDVA）、主观和客观验光、内皮细胞计数（ECC）、眼压、生物显微镜检查结果以及患者报告的症状。
19例患者的28只眼术前近视度数在-1.00 D至-12.00 D之间，散光度数在-1.00 D至-5.50 D之间，植入Artiflex环曲面PIOL以矫正屈光不正。术后，所有眼的UCVA至少为6/12，94%的眼至少为6/9，58%的眼至少为6/6。38%的眼CDVA提高，1只眼视力下降1行。术后平均等效球镜度为-0.25 D（范围为-1.25 D至0.00 D），平均散光为-0.60 D（范围为-1.50 D至0.00 D）。与术前基线相比，12个月时ECC平均下降6.17%（标准差5.63%）。
Artiflex环曲面PIOL是治疗中高度屈光不正合并散光的一种有效、可预测且安全的方法。
